Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, multi-site, open-label, non-randomized clinical trial evaluating the
safety, tolerability, and pharmacokinetics of escalating doses of olaparib and trabectedin in
patients with unresectable advanced/metastatic sarcomas. Patients will continue to be treated
on this combination regimen in the absence of disease progression, intolerable toxicity or
patient's decision.
Phase:
Phase 1
Details
Lead Sponsor:
Italian Sarcoma Group
Collaborators:
AstraZeneca Istituto Di Ricerche Farmacologiche Mario Negri PharmaMar